Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Many PRIME Applicants Are Missing Pediatric Investigation Plans

Executive Summary

Aside from pediatrics research issue, most of the first batch of applications for the new priority review scheme were "in scope," with numerous therapeutic areas targeted.


Related Content

First EU PRIME Designations Go To Biogen, ChemoCentryx, Kite, NovImmune
EMA's PRIME: Helpful But Not A Panacea
EMA, FDA Get Together On Drugs Eligible For PRIME And Breakthrough Designation
EMA's Early Pediatric Advice Pilot Has Mixed Results
PRIME Time: Smaller Companies In Focus As EMA Launches Priority Medicines Scheme